AstraZeneca PLC (AZN)
| Market Cap | 300.86B +25.4% |
| Revenue (ttm) | 58.74B +8.6% |
| Net Income | 10.23B +45.3% |
| EPS | 6.54 +45.3% |
| Shares Out | 1.55B |
| PE Ratio | 29.42 |
| Forward PE | 18.85 |
| Dividend | $3.20 (1.59%) |
| Ex-Dividend Date | Feb 20, 2026 |
| Volume | 1,353,208 |
| Open | 198.89 |
| Previous Close | 197.22 |
| Day's Range | 198.72 - 201.74 |
| 52-Week Range | 122.26 - 212.71 |
| Beta | 0.23 |
| Analysts | Strong Buy |
| Price Target | n/a |
| Earnings Date | Apr 28, 2026 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial StatementsNews
AstraZeneca Scores Pediatric Win While Adult Trial Falls Short In Rare Bone Disease
AstraZeneca reports mixed Phase 3 data for efzimfotase alfa in HPP and positive COPD results for tozorakimab; shares rise on updates. ... Full story available on Benzinga.com
AstraZeneca Confident Rare-Disease Drug Can Hit Target After Mixed Study Results
The company said the results support the drug's potential to transform the treatment of hypophosphatasia and it plans to submit data to regulators as soon as possible.
AstraZeneca: Efzimfotase Alfa Shows Positive Results From Phase III Programme
(RTTNews) - AstraZeneca (AZN, AZN.L, ZEG.DE, AZN.ST) said the efzimfotase alfa or ALXN1850 Phase III clinical programme, designed to study a broad hypophosphatasia patient population, demonstrated pos...
If You Invested $1000 In AstraZeneca Stock 10 Years Ago, You Would Have This Much Today
AstraZeneca (NYSE: AZN) has outperformed the market over the past 10 years by 1.12% on an annualized basis producing an average annual return of 13.13%. Currently, AstraZeneca has a market capitaliza...
AstraZeneca stock jumps as COPD drug trial win surprises market
Shares of AstraZeneca rose on Friday after the drugmaker reported positive results from late-stage clinical trials of its experimental chronic obstructive pulmonary disease (COPD) treatment, tozorakim...
AstraZeneca Stock Rises 4% Over Positive Data From Tozorakimab Study
(RTTNews) - Shares of AstraZeneca PLC (AZN) are gaining about 4 percent on Friday morning trading after the company announced positive high-level results from the Phase III OBERON and TITANIA trials i...
Stocks to Watch: Unity, Carnival, AstraZeneca
AstraZeneca Zips Higher On Its Double Win In COPD Treatment
AstraZeneca stock jumped Friday after the U.K.-based drugmaker said its COPD drug succeeded in two final-phase studies.
AstraZeneca stock jumps 4% after surprise trial win for lung disease drug where rivals have failed
Britain's most valuable company said its experimental lung disease medicine met its target in two late-stage clinical trials. The respiratory treatment Tozorakimab, reduced flare-ups of chronic obstru...
AstraZeneca Strengthens Position In COPD Race With Successful Trials
AstraZeneca reports Phase 3 success for tozorakimab in COPD, reducing exacerbations and showing strong safety across broad patient groups. ... Full story available on Benzinga.com
Stocks making the biggest moves premarket: AstraZeneca, Unity Software, Coinbase & more
These are the stocks posting the largest moves premarket.
Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the Phase III OBERON and TITANIA trials in patients with chronic obstructive pulmonary disease (COPD) showed that tozorakimab reduce...
AstraZeneca Lung Disease Drug Candidate Hits Goals in Late-Stage Trials
Tozorakimab met the primary goal in two late-stage clinical trials, reducing the rate at which patients' symptoms worsened, the company said.
AstraZeneca's Tozorakimab Meets Primary Endpoint In Phase III COPD Trials
(RTTNews) - AstraZeneca Plc. (AZN, AZN.L, ZEG.DE, AZN.ST) announced positive high-level results from the Phase III OBERON and TITANIA trials in patients with chronic obstructive pulmonary disease (COP...
AstraZeneca drug reduces COPD flare ups in late-stage trials
AstraZeneca said on Friday said its experimental treatment tozorakimab met the main goal in two late-stage trials and showed a meaningful reduction in flare ups of chronic obstructive pulmo...
Final Trade: AZN, VIX, IWM
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
‘My organs shut down, now I’m in a wheelchair’: The lives ruined by Covid jabs
Having been a dental nurse for more than a decade, Nikola Brindley was familiar with vaccination requirements for healthcare workers. So when she was asked to have AstraZeneca’s Covid jab in July 2021...
Abivax CEO Downplays Sale Talk, Eyes Capital Raise As Key Trial Data Readout Nears
Abivax SA (NASDAQ: ABVX) is preparing to raise capital following the release of key clinical trial data in June, signaling a preference for independent growth despite ongoing acquisition speculation,...
Global drug giants double down on China amid trend to build self-reliant supply chains
AstraZeneca said it would establish drug manufacturing facilities in Guangzhou and Shanghai as well as a separate innovation centre in Shanghai, joining a group of foreign players building new plants ...
AstraZeneca to build Shanghai mega-plant as it steps up investment in China after snubbing UK
The pharmaceutical giant will build a manufacturing hub and innovation centre as it invests £108bn in China before 2030 to make cell therapies.
Jacobio Pharma Poised To Turn A Profit From Precision Cancer Drugs
The Chinese firm is pocketing an upfront payment for a gene-focused drug under development and anticipates rising sales of an approved treatment for lung cancer image credit: Bamboo Works Key Takeaway...
AstraZeneca says it will build cell therapy base, innovation centre in Shanghai
AstraZeneca said on Thursday it will build a cell therapy manufacturing and supply base and innovation centre in Shanghai, aiming to become the first global drugmaker with end-to-end cell thera...
TrumpRx lists many medicines at prices higher than paid in UK
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those ...
Challenges for AstraZeneca (AZN) Amid Drug Pricing Claims
Challenges for AstraZeneca (AZN) Amid Drug Pricing Claims
Big drugmakers must face US overcharge claims on medications for low-income patients
A U.S. appeals court on Tuesday revived a whistleblower lawsuit accusing four large drugmakers of defrauding the federal and state governments out of hundreds of millions of dollars by overcharging ...